MCID: CHR066
MIFTS: 64

Chronic Fatigue Syndrome malady

Categories: Rare diseases, Neuronal diseases, Immune diseases

Aliases & Classifications for Chronic Fatigue Syndrome

About this section

Aliases & Descriptions for Chronic Fatigue Syndrome:

Name: Chronic Fatigue Syndrome 11 48 50 38 2 13 68
Cfs 11 2 13
Myalgic Encephalomyelitis 11 48
Chronic Fatigue Immune Dysfunction Syndrome 48
 
Systemic Exertion Intolerance Disease 48
Postviral Fatigue Syndrome 11
Fatigue Syndrome, Chronic 39
Myalgic Encephalitis 11

Classifications:



Summaries for Chronic Fatigue Syndrome

About this section
MedlinePlus:38 Chronic fatigue syndrome (cfs) is a disorder that causes extreme fatigue. this fatigue is not the kind of tired feeling that goes away after you rest. instead, it lasts a long time and limits your ability to do ordinary daily activities. the main symptom of cfs is severe fatigue that lasts for 6 months or more. you also have at least four of these other symptoms: feeling unwell for more than 24 hours after physical activity muscle pain memory problems headaches pain in multiple joints sleep problems sore throat tender lymph nodes cfs is hard to diagnose. there are no tests for it, and other illnesses can cause similar symptoms. your doctor has to rule out other diseases before making a diagnosis of cfs. no one knows what causes cfs. it is most common in women in their 40s and 50s, but anyone can have it. it can last for years. there is no cure for cfs, so the goal of treatment is to improve symptoms. cfs affects people in different ways. you should work with your doctors to create a treatment program that best meets your own needs. it may include therapies to manage your symptoms, such as medicines to treat pain, sleep disorders, and other problems. it may also include coping techniques, and ways of managing your daily activities. centers for disease control and prevention

MalaCards based summary: Chronic Fatigue Syndrome, also known as cfs, is related to ulcerative colitis and obesity, and has symptoms including other fatigue, other malaise and sluggishness. An important gene associated with Chronic Fatigue Syndrome is RNASEL (Ribonuclease L), and among its related pathways are Glucocorticoid Pathway (HPA Axis), Pharmacodynamics and Neurotransmitter Clearance In The Synaptic Cleft. The drugs coenzyme q10 and fish oils have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and heart, and related mouse phenotypes are Decreased viability with paclitaxel and Synthetic lethal with MLN4924 (a NAE inhibitor).

Disease Ontology:11 A syndrome that involves prolonged and severe tiredness or weariness that is unrelated to exertion, is not relieved by rest and for a minimum of six months and is not directly caused by other conditions.

NIH Rare Diseases:48 Chronic fatigue syndrome, also known as systemic exertion intolerance disease, is a condition that causes extreme, long-lasting fatigue which can limit the ability to participate in ordinary, daily activities. It generally occurs in young adults (20 to 40 years of age) and is twice as common in women. The main symptom is disabling fatigue that does not improve with rest. Other signs and symptoms may include muscle pain, joint pain, concentration and memory problems, headaches, sleep problems, fever, sore throat, and/or tender lymph nodes. The exact cause is not known. There is still no cure or effective treatment for this condition but there are several clinical trials. There is controversy and debate in the medical literature about the relationship between myalgic encephalomyelitis and chronic fatigue syndrome and there is no consensus on nomenclature or classification for these disorders. Different countries, organizations, and researchers continue to use different names to describe these conditions. Last updated: 10/18/2016

CDC:2 Chronic fatigue syndrome, or CFS, is a debilitating and complex disorder characterized by profound fatigue that is not improved by bed rest and that may be worsened by physical or mental activity. Symptoms affect several body systems and may include weakness, muscle pain, impaired memory and/or mental concentration, and insomnia, which can result in reduced participation in daily activities.

Wikipedia:71 Chronic fatigue syndrome (CFS) is a medical condition characterized by long-term fatigue and other... more...

Related Diseases for Chronic Fatigue Syndrome

About this section

Diseases related to Chronic Fatigue Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 372)
idRelated DiseaseScoreTop Affiliating Genes
1ulcerative colitis29.3COMT, IGF1, IL1B, IL6, SLC6A4
2obesity28.7IGF1, IL1B, IL6, NR3C1, POMC, TNF
3addison's disease28.4CXCL8, IL10, IL2, TGFB1, TNF
4rheumatoid arthritis27.5CXCL8, IL10, IL1B, IL2, IL6, TGFB1
5corticosteroid-binding globulin deficiency10.7
6persian gulf syndrome10.7
7prosopagnosia10.7CRH, NR3C1, POMC
8cold-induced sweating syndrome 210.6CRH, NR3C1, POMC
9acute myocarditis10.6CRH, NR3C1, POMC
10loeffler endocarditis10.6CRH, NR3C1, POMC
11nasopharyngeal disease10.6CRH, NR3C1, POMC
12intrahepatic gall duct cancer10.6CRH, MAOA, SLC6A4
13multiple mitochondrial dysfunctions syndrome10.5CRH, IGF1, POMC
14paget disease of bone 410.5IL10, IL2, NR3C1
15balkan hemorrhagic fever10.5COMT, IL10
16corpus luteum cyst10.5CRH, IGF1, POMC
17chronic salpingo-oophoritis10.5CRH, NR3C1, POMC
18heroin dependence10.5CRH, POMC, SLC6A4
19cardiovascular organ benign neoplasm10.5CRH, IGF1, POMC
20hemorrhagic cystitis10.5COMT, MAOA, SLC6A4
21hemoglobinopathy10.5IL1B, IL6, POMC
22tongue disease10.5COMT, MAOA, SLC6A4
23lymphosarcoma10.5COMT, POMC, SLC6A4
24vestibular gland benign neoplasm10.5CRH, IGF1, POMC
25tinea pedis10.5HTR1A, IL6, SLC6A4
26nonencapsulated sclerosing carcinoma10.4HTR1A, MAOA, SLC6A4
27midline interhemispheric variant of holoprosencephaly10.4IL1B, IL2, IL6
28pyromania10.4HTR1A, MAOA, SLC6A4
29anosognosia10.4COMT, HTR1A, SLC6A4
30malignant peripheral nerve sheath tumor10.4HTR1A, MAOA, SLC6A4
31skull base neoplasm10.4CRH, IGF1, POMC
32periodic paralyses10.4IL1B, IL2, IL6
33jejunal somatostatinoma10.4IL10, IL2, IL6
34neurodegeneration with optic atrophy, childhood onset10.4COMT, HTR2A, SLC6A4
35phlegmonous dacryocystitis10.4COMT, MAOA, POMC, SLC6A4
36chagas disease10.4HTR2A, MAOA, SLC6A4
37pervasive developmental disorder10.3COMT, POMC, SLC6A4
38piepkorn karp hickok syndrome10.3IL10, TNF
39conjunctival degeneration10.3HTR1A, HTR2A, SLC6A4
40central sleep apnea10.3HTR1A, HTR2A, SLC6A4
41linitis plastica10.3IL2, TNF
42osteopetrosis10.3IGF1, NR3C1, TGFB1
43thyroid malformation10.3IL1B, TNF
446q terminal deletion syndrome10.2IL10, TNF
45calcifying epithelial odontogenic tumor10.2IL10, IL2, TGFB1
46lymphocytic colitis10.2IL6, SLC6A4, TNF
47leukemia10.2
48paranoid personality disorder10.2HTR1A, HTR2A
49splenic manifestation of prolymphocytic leukemia10.2IL2, IL6, TNF
50hematologic cancer10.2HTR2A, TGFB1

Graphical network of the top 20 diseases related to Chronic Fatigue Syndrome:



Diseases related to chronic fatigue syndrome

Symptoms & Phenotypes for Chronic Fatigue Syndrome

About this section

UMLS symptoms related to Chronic Fatigue Syndrome:


other fatigue, other malaise, sluggishness, asthenic conditions, other malaise and fatigue, weakness/tiredness general, myalgia, malaise, signs and symptoms of ill-defined conditions, muscle weakness, hypokinesia, apathy, sciatica, pruritus, muscle spasticity, muscle rigidity, muscle cramp, malaise and fatigue, lethargy, fatigue, cachexia, back pain, asthenia

GenomeRNAi Phenotypes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00293-A9.5IGF1, IL10, TGFB1
2GR00250-A-14.2CXCL8, EIF2AK2, IL10, IL1B, IL2, PDCD2

MGI Mouse Phenotypes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

41 (show all 19)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053708.8CRH, IL10, IL2, IL6, NR3C1, POMC
2MP:00053678.4COMT, CRH, IGF1, IL6, NR3C1, POMC
3MP:00053758.3CRH, IGF1, IL6, NR3C1, POMC, TGFB1
4MP:00053888.1COMT, CRH, IGF1, IL10, IL2, IL6
5MP:00107718.0CRH, IGF1, IL10, IL1B, IL6, NR3C1
6MP:00053897.9COMT, IGF1, IL10, IL2, IL6, NR3C1
7MP:00053697.8HTR2A, IGF1, IL10, IL6, NR3C1, SLC6A4
8MP:00020067.6EIF2AK2, IGF1, IL10, IL1B, IL2, IL6
9MP:00053907.4CRH, HTR2A, IGF1, IL10, IL1B, IL6
10MP:00053847.3CRH, EIF2AK2, IGF1, IL10, IL2, IL6
11MP:00053787.0CRH, IGF1, IL10, IL2, IL6, NR3C1
12MP:00036316.9COMT, CRH, HTR1A, IGF1, IL10, IL1B
13MP:00053796.9COMT, CRH, HTR2A, IGF1, IL10, IL2
14MP:00053866.8COMT, CRH, HTR1A, HTR2A, IL10, IL2
15MP:00053856.7COMT, HTR1A, IGF1, IL10, IL1B, IL2
16MP:00053876.5COMT, CRH, EIF2AK2, IGF1, IL10, IL1B
17MP:00053976.4COMT, CRH, EIF2AK2, IGF1, IL10, IL1B
18MP:00053766.2COMT, CRH, HTR1A, IGF1, IL10, IL1B
19MP:00107685.9EIF2AK2, HTR1A, IGF1, IL10, IL1B, IL2

Drugs & Therapeutics for Chronic Fatigue Syndrome

About this section

Drugs for Chronic Fatigue Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 258)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DopamineapprovedPhase 4, Phase 2, Phase 3375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
2
DinoprostoneapprovedPhase 488363-24-65280360
Synonyms:
(15S)-Prostaglandin E2
(15S)-Prostaglandin e2
(5Z,11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
(5Z,11.alpha.,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
(5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic
(5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid
(5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
(5Z,11alpha,13e,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
(5Z,13e)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate
(5Z,13e)-(15S)-11alpha,15-Dihydroxy-9-oxoprosta-5,13-dienoate
(E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid
(Z)-7-((1R,2R,3R)-3-Hydroxy-2-((S,e)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid
(Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
(e,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid
05D31BD5-818B-4A92-8CFC-BEC19926A5B3
363-24-6
5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)- (8CI)
7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid
AC-6098
AC1NQWXW
BML1-F07
BMS-279654 & PGE2
BRD-K26521938-001-04-9
BSPBio_001490
C00584
CHEBI:15551
CHEMBL548
CID5280360
Cervidil
Cervidil (TN)
D00079
D015232
DB00917
Dinoproston
Dinoprostona
Dinoprostona [INN-Spanish]
Dinoprostone
Dinoprostone (JAN/USP/INN)
Dinoprostone Prostaglandin E2
Dinoprostone [USAN:INN:BAN:JAN]
Dinoprostone beta-Cyclodextrin Clathrate
Dinoprostonum
Dinoprostonum [INN-Latin]
E2 alpha, Prostaglandin
E2, Prostaglandin
E2alpha, Prostaglandin
EINECS 206-656-6
Gel, Prepidil
 
HMS1361K12
HMS1791K12
HMS1989K12
HMS2089D17
IDI1_033960
LMFA03010003
LS-125823
Minprositin E2
Minprostin E2
MolPort-003-939-184
NCGC00092361-01
NCGC00092361-02
NCGC00092361-03
NCGC00092361-04
NCGC00092361-05
NSC 165560
NSC 196514
P0409_SIGMA
P5640_SIGMA
P6532_SIGMA
PGE2
PGE2 alpha
PGE2alpha
Prepidil
Prepidil (TN)
Prepidil Gel
Prestwick_793
Propess
Prostaglandin E2
Prostaglandin E2 alpha
Prostaglandin E2alpha
Prostarmon E
Prostarmon E2
Prostenon
Prostin
Prostin E
Prostin E2
Prostin E2 (TN)
Prostin e2
SMP2_000056
ST50826265
U 12062
U-12062
UNII-K7Q1JQR04M
[3H]PGE2
alpha, PGE2
alpha, Prostaglandin E2
l-7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid
l-PGE2
l-Prostaglandin E2
nchembio.106-comp6
nchembio.147-comp12
3
Sodium oxybateapprovedPhase 438502-85-25360545
Synonyms:
4-Hydroxybuttersaeure natriumsalz
4-Hydroxybutyrate sodium
4-Hydroxybutyric acid monosodium salt
4-Hydroxybutyric acid sodium salt
502-85-2
ARONIS24196
Anetamin
BUTYRIC ACID, 4-HYDROXY-, SODIUM SALT
Butanoic acid, 4-hydroxy-, monosodium salt
Butanoic acid, 4-hydroxy-, sodium salt
Butanoic acid, 4-hydroxy-, sodium salt (1:1)
Butyric acid, 4-hydroxy-, monosodium salt
Butyric acid, 4-hydroxy-, monosodium salt (8CI)
C4H7O3.Na
CHEMBL1200682
CID10412
D05866
EB 27
EINECS 207-953-3
GHB
Gamma OH
H-4040
H3635_SIGMA
HMS2091E15
Hydroxybutyric acid monosodium salt
 
LS-48077
MolPort-001-766-711
MolPort-006-717-541
NSC 84223
Natrium 4-hydroxybutyrat
OR28769
Oxybate sodium
Sodium 4-hydroxybutyrate
Sodium Oxybate [USAN]
Sodium Oxybutyrate
Sodium gamma-hydroxybutyrate
Sodium gammahydroxybutyrate
Sodium oxybate
Sodium oxybate (USAN)
Sodium-4-hydroxybutyrate
Somsanit
UNII-7G33012534
WY 3478
WY-3478
Xyrem
Xyrem (TN)
gamma-Hydroxy sodium butyrate
gamma-Hydroxybutyrate sodium
gamma-Hydroxybutyrate sodium salt
gamma-Hydroxybutyric acid sodium salt
gamma-Hydroxybutyric acid, sodium salt
4
Tetracyclineapproved, vet_approvedPhase 49960-54-85353990
Synonyms:
(-)-Tetracycline
(4S,4AS,5as,12as)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
6-Methyl-1,11-dioxy-2-naphthacenecarboxamide
60-54-8
64-75-5 (mono-hydrochloride)
6591-49-7
87128_FLUKA
87128_SIGMA
AC-13151
AC1L1KAT
AC1NQXT7
AC1NRDAM
AC1NS4RQ
AC1NSDX8
AC1NTUT2
AC1NUZHL
AC1O52HS
Abramycin
Abricycline
Achromycin
Achromycin (naphthacene derivative)
Achromycin V
Achromycin, naphthacene derivative
Agromicina
Ambramicina
Ambramycin
Amycin
Anhydrotetracycline
BIDD:GT0653
BPBio1_000242
BSPBio_000220
BSPBio_001950
Bio-tetra
Biocycline
Bristaciclin
Bristaciclin .alpha.
Bristaciclina
Bristacycline
C06570
CHEBI:27902
CHEMBL1440
CID12309720
CID5280962
CID5289435
CID5353990
CID5359245
CID5388997
CID5412
CID5497101
CID6426717
Cefracycline
Cefracycline suspension
Centet (base)
Ciclibion
Copharlan
Criseociclina
Cyclomycin
Cyclopar
Cytome
D00201
DB00759
Democracin
Deschlorobiomycin
DivK1c_000827
Dumocyclin
EINECS 200-481-9
Enterocycline
HMS2090B04
HSDB 3188
Hostacyclin
IDI1_000827
KBio1_000827
KBio2_001514
KBio2_004082
KBio2_006650
KBio3_001450
KBioGR_000783
KBioSS_001514
LS-187078
LS-93869
Lemtrex (base)
Lexacycline
Limecycline
Liquamycin
Liquamycin (Veterinary)
 
Liquamycin, veterinary
MLS000069728
Medocycline
Mericycline
Micycline
MolPort-001-794-633
MolPort-003-983-460
MolPort-005-934-198
NCGC00161665-01
NINDS_000827
NSC 108579
NSC108579
Neocycline
Omegamycin
Orlycycline
Panmycin
Piracaps (base)
Polycycline
Polycycline (VAN)
Polycycline (antibiotic)
Polycycline, antibiotic
Polyotic
Prestwick0_000140
Prestwick1_000140
Prestwick2_000140
Prestwick3_000140
Purocyclina
Resteclin
Robitet
Roviciclina
SK-Tetracycline
SMR000058220
SPBio_001457
SPBio_002159
STOCK1N-42738
Sanclomycine
Solvocin
Spectrum2_001329
Spectrum3_000565
Spectrum4_000352
Spectrum5_001112
Spectrum_001034
Sumycin
Sumycin (TN)
Sumycin syrup
T-125
T3258_SIGMA
Tetra-Co
Tetrabon
Tetrachel
Tetraciclina
Tetraciclina [INN-Spanish]
Tetracycl
Tetracyclin
Tetracycline & VRC3375
Tetracycline (JAN/USP/INN)
Tetracycline (internal use)
Tetracycline Free Base
Tetracycline HCl
Tetracycline I
Tetracycline II
Tetracycline Monohydrochloride
Tetracycline [USAN:INN:BAN:JAN]
Tetracyclinum
Tetracyclinum [INN-Latin]
Tetracyn
Tetradecin
Tetrafil
Tetraverine
Tetrazyklin
Topicycline
Tsiklomistsin
Tsiklomitsin
Tétracycline
UNII-F8VB5M810T
UPCMLD-DP127
UPCMLD-DP127:001
UPCMLD-DP127:002
Veracin
Vetacyclinum
Vetquamycin-324 (free base)
WLN: L E6 C666 BV FV CU GUTTT&J DQ EQ GVZ HQ IN1&1 MQ M1 RQ
component of Tetrastatin
methyl-1,11-dioxo-2-naphthacenecarboxamide
nchembio.273-comp1
nchembio.289-comp1
tetracycline
5
Doxycyclineapproved, investigational, vet_approvedPhase 4237564-25-054671203
Synonyms:
(2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10597-92-9
17086-28-1 (mono-hydrate)
2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)
24390-14-5
41411-66-9 (6-epimer, mono-hydrochloride)
5-Hydroxy-alpha-6-deoxytetracycline
5-hydroxy-α-6-deoxytetracycline
564-25-0
6-Deoxyoxytetracycline
6-Deoxytetracycline
6-alpha-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
69935-17-7 (mono-hydrochloride, di-hydrate)
6alpha-Deoxy-5-oxytetracycline
6alpha-deoxy-5-oxytetracycline
6α-deoxy-5-oxytetracycline
7164-70-7
7264-10-0
94088-85-4 (calcium salt (1:2))
AB08 (*Fosfatex)
AC1NQXW7
AC1NS4CW
AC1NUYS8
AC1O8PYM
Alti-Doxycycline
Anhydrous doxycycline
Apo-Doxy
Atridox
Azudoxat
BCBcMAP01_000024
BIDD:GT0146
BMY-28689
BPBio1_000951
BSPBio_000863
BSPBio_001936
BU-3839T
C06973
CHEBI:50845
CHEMBL1433
CID5281011
CID5353597
CID5463943
CID6713981
CPD001550033
D07876
DB00254
DMSC (*Fosfatex)
DOXCYCLINE ANHYDROUS
DOXY
DOXYCYCLINE CALCIUM
DOXYCYCLINE MONOHYDRATE
Deoxymykoin
DivK1c_000345
Dossiciclina
Dossiciclina [DCIT]
Doxcycline anhydrous
Doxiciclina
Doxiciclina [INN-Spanish]
Doxiciclina [Italian]
Doxitard
Doxivetin
Doxy-Caps
Doxy-Puren
Doxy-Tabs
Doxycen
Doxychel
Doxychel (TN)
Doxycin
Doxycyclin
Doxycycline (200mg/day) or Placebo
 
Doxycycline (INN)
Doxycycline (TN)
Doxycycline (anhydrous)
Doxycycline (internal use)
Doxycycline Hyclate
Doxycycline Monohydrate
Doxycycline anhydrous
Doxycycline hyclate
Doxycycline-Chinoin
Doxycyclinum
Doxycyclinum [INN-Latin]
Doxysol
Doxytec
Doxytetracycline
EINECS 209-271-1
GS-3065 (*monohydrate)
HMS2090E06
HSDB 3071
Hydramycin
IDI1_000345
Investin
Jenacyclin
KBio1_000345
KBio2_001287
KBio2_003855
KBio2_006423
KBio3_001156
KBioGR_001133
KBioSS_001287
LS-187766
LS-93868
Liviatin
Lopac0_000405
MolPort-002-507-423
Monodox
Monodox (*monohydrate)
NCGC00161602-01
NCGC00161602-03
NCGC00161602-04
NCGC00167961-01
NCGC00179395-01
NINDS_000345
NSC633557
Novo-Doxylin
Nu-Doxycycline
Oracea
Prestwick0_000852
Prestwick1_000852
Prestwick2_000852
Prestwick3_000852
Ronaxan
SAM002589932
SMP1_000107
SPBio_000246
SPBio_002784
STOCK1N-34341
Spanor
Spectrum2_000143
Spectrum3_000408
Spectrum4_000527
Spectrum5_000947
Spectrum_000807
Supracyclin
UNII-334895S862
UPCMLD-DP021
UPCMLD-DP021:001
Vibra-tabs
Vibramycin
Vibramycin (*monohydrate)
Vibramycin Novum
Vibramycine
Vibravenos
Vivox (*Hyclate)
alpha-6-Deoxy-5-hydroxytetracycline
alpha-6-Deoxyoxytetracycline
alpha-Doxycycline
doxycycline
6
MilnacipranapprovedPhase 4, Phase 35992623-85-365833
Synonyms:
( -)-Milnacipran
(+-)-cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
(-)-milnacipran
(1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane HCl
105310-09-6
92623-85-3
AC1L2425
CHEMBL252923
CID65833
D08222
DB04896
F 2207
 
F-2207
F2207
Ixel
LS-178180
Midalcipran
Milnacipran
Milnacipran (INN)
Milnacipran [INN]
Milnacipranum
Milnacipranum [Latin]
Milnacipranum [latin]
NCGC00165825-01
Toledomin
UNII-G56VK1HF36
milnacipran
7
BenzocaineapprovedPhase 4, Phase 318921994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
8
RibavirinapprovedPhase 4, Phase 398436791-04-537542
Synonyms:
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
36791-04-5
437710-49-1
66510-90-5
AA-504/07617051
AB00430481
AC1L1XXZ
AC1Q1IDC
AC1Q4ZGS
AKOS001715163
BB_NC-0567
BPBio1_001195
BRN 0892462
BSPBio_001085
BSPBio_003352
C-Virin
CHEMBL1643
CID37542
Copegus
Copegus (TN)
Cotronak
D00423
DB00811
DRG-0028
DivK1c_000782
Drug: Ribavirin
EU-0101063
FT-0082885
HMS2090L15
HMS2094O09
HMS502H04
HSDB 6513
ICN-1229
IDI1_000782
KBio1_000782
KBio2_002328
KBio2_004896
KBio2_007464
KBio3_002854
KBioGR_001804
KBioSS_002331
KS-1104
LS-1241
Lopac0_001063
MLS000028486
MLS002222317
MolPort-002-507-104
MolPort-002-885-856
NCGC00090726-01
NCGC00090726-03
NCGC00090726-04
NCGC00090726-05
NCGC00090726-06
NCGC00090726-07
NINDS_000782
NSC 163039
 
NSC163039
Prestwick3_000993
R 9644
R-964
R9644_SIGMA
RBV
RG-964
RIBAV
RTC
RTCA
RTP
Ravanex
Rebetol
Rebetol (TN)
Rebetron
Rebretron
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribav
Ribavirin
Ribavirin (JAN/USP/INN)
Ribavirin Capsules
Ribavirin Triphosphate
Ribavirin [USAN:INN]
Ribavirin-TP
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirinum
Ribavirinum [INN-Latin]
Ribovirin
Ro 20-9963/000
Ro-20-9963
S2504_Selleck
SCH 18908
SMP1_000261
SMR000058315
SPECTRUM1503938
SR-01000076112-3
Spectrum3_001876
Spectrum4_001252
Spectrum5_002075
Spectrum_001826
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Viramid
Viramide
Virazid
Virazide
Virazole
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
Virazole 5'-triphosphate
ZINC01035331
ribavirin
9
ZincapprovedPhase 422317440-66-632051, 23994
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
10
Melatoninapproved, nutraceutical, vet_approvedPhase 4, Phase 2, Phase 3, Phase 125573-31-4896
Synonyms:
0E2B08C1-B325-45B1-8939-6F9081EFDFA4
4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID
5-22-12-00042 (Beilstein Handbook Reference)
5-Methoxy-N-acetyltryptamine
5-methoxy-N-acetyltryptamine
73-31-4
A4039/0172195
AB00053279
AC1L1A9Q
AC1Q4F1W
AC1Q4F1X
AKOS000276269
Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)- (9CI)
Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI)
Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]- (6CI,8CI)
Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}
Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}
BAS 01281092
BIDD:ER0618
BPBio1_000590
BRD-K97530723-001-07-6
BRN 0205542
BSPBio_000536
BSPBio_003006
Bio-0635
C01598
CAS-73-31-4
CCRIS 3472
CHEBI:16796
CHEMBL45
CID896
ChemDiv2_003916
Circadin
D008550
D08170
DB01065
DB08189
DivK1c_000353
EINECS 200-797-7
EU-0100787
HMS1380B22
HMS1569K18
HMS1921E04
HMS2089F09
HMS501B15
HSCI1_000400
HSDB 7509
I05-0076
I10-0345
IDI1_000353
IDI1_002631
IN1244
KBio1_000353
KBio2_000665
KBio2_003233
KBio2_005801
KBio3_002226
KBioGR_000591
KBioSS_000665
L001261
LS-1623
Lopac-M-5250
Lopac0_000787
M 5250
M-1200
M-1250
M1105
M5250_SIGMA
ML1
MLS000859594
MLS001055382
MLS001240204
MT6
Mela-T
Melapure
Melatol
Melatonex
Melatonex, Melatonin
Melatonin
Melatonin (synth.) standard-grade
 
Melatonin (synth.) ultra-pure
Melatonina
Melatonina (TN)
Melatonine
Melovine
MolPort-000-737-883
N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)-Acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide
N-Acetyl-5-methoxy-tryptamine
N-Acetyl-5-methoxy-tryptamine Melatonine
N-Acetyl-5-methoxytryptamine
N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-Acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]-Acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide
N-[2-(5-methoxyindol-3-yl)ethyl]acetamide
N-acetyl-5-methoxy-tryptamine
NCGC00015680-01
NCGC00015680-02
NCGC00015680-03
NCGC00015680-06
NCGC00015680-13
NCGC00090727-01
NCGC00090727-02
NCGC00090727-03
NCGC00090727-04
NCGC00090727-05
NCGC00090727-06
NCGC00090727-07
NCGC00090727-08
NCGC00090727-09
NCI60_004378
NINDS_000353
NMR/14327425
NSC 113928
NSC113928
NSC56423
Nature'S Harmony
Night Rest
Oprea1_104553
Oprea1_814234
PREVENTION 1 (MELATONIN) (PREVENTION 1)
PREVENTION 2 (MELATONIN)
PREVENTION 3 (MELATONIN)
PREVENTION 4 (MELATONIN)
PREVENTION 5 (MELATONIN)
Pineal Hormone
Posidorm
Prestwick0_000458
Prestwick1_000458
Prestwick2_000458
Prestwick3_000458
Prestwick_312
Regulin
Revital Melatonin
Rx Balance
S1204_Selleck
SDCCGMLS-0065812.P001
SDCCGMLS-0065812.P002
SMP2_000309
SMR000326666
SPBio_001527
SPBio_002475
SPECTRUM1500690
STK386880
Sleep Right
Spectrum2_001344
Spectrum3_001393
Spectrum4_000066
Spectrum5_001745
Spectrum_000185
TNP00300
UNII-JL5DK93RCL
Vivitas
WLN: T56 BMJ D2MV1 GO1
ZINC00057060
{N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-} Acetamide
{N-[2-(5-methoxyindol-3-yl)ethyl]-} Acetamide
11
Ergocalciferolapproved, nutraceuticalPhase 4123250-14-65280793
Synonyms:
'Ergosterol irradiated'
(+)-Vitamin D2
(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol
(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7e,22e)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,Secoergosta-5,7,10(19)-ol
31316-19-5
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3aH)-indanylidene]ethylidene]-Cyclohexanol
47768_SUPELCO
50-14-6
7489-18-1
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87
8017-28-5
9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol
9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
95220_FLUKA
95220_SIGMA
AC-1355
AC1L1FIE
AC1NQXLH
AC1NS4DE
AC1NS9GI
AC1NSSVD
AC1NWAM3
AC1O5EDK
AC1O6WAM
ACon1_002187
Activated ergosterol
BPBio1_000418
BSPBio_000380
BSPBio_001974
Buco-D
C05441
C28H44O
CALCIFEROL IN A GELATIN MATRIX
CALCIFEROL, U.S.P.
CHEBI:28934
CHEMBL1536
CID11003810
CID3249
CID5280793
CID5315257
CID5353610
CID5356615
CID5702050
CID6432478
CID6536972
Calciferol
Calciferol (TN)
Calciferol (vitamin D2)
Calciferolum
Calciferon 2
Condacaps
Condocaps
Condol
Crtron
Crystallina
D-Arthin
D-Tracetten
D00187
DB00153
Daral
Davitamon D
Davitin
De-rat concentrate
Decaps
Dee-Osterol
Dee-Ron
Dee-Ronal
Dee-Roual
Deltalin
Deratol
Detalup
Diactol
Divit urto
Doral
Drisdol
Drisdol (TN)
E5750_SIGMA
EINECS 200-014-9
Ercalciol
Ergocalciferol
Ergocalciferol (D2)
Ergocalciferol (JP15/USP)
Ergocalciferol [INN:BAN:JAN]
Ergocalciferol oil
Ergocalciferol: Vitamin D
 
Ergocalciferolo
Ergocalciferolo [DCIT]
Ergocalciferols
Ergocalciferolum
Ergocalciferolum [INN-Latin]
Ergorone
Ergosterol activated
Ergosterol irradiated
Ergosterol, irradiated
Ertron
Fortodyl
Geltabs
Geltabs Vitamin D
HMS1920K20
HMS2091B19
HMS502I07
HSDB 819
Haliver
Hi-Deratol
Hyperkil
I05-0022
IDI1_000805
Infron
Irradiated ergosta-5,7,22-trien-3-beta-ol
Irradiated ergosta-5,7,22-trien-3.beta.-ol
Irradiated ergosta-5,7,22-trien-3beta-ol
Irradiated ergosterol
LMST03010001
LMST03010014
LS-3228
MEGxm0_000466
MLS001332467
MLS001332468
Metadee
Mina D2
MolPort-001-740-057
MolPort-001-793-930
MolPort-002-526-645
MolPort-003-666-178
MolPort-006-822-629
Mulsiferol
Mykostin
NCGC00142497-01
NCGC00179579-01
NCGC00179579-02
NSC 62792
NSC62792
Novovitamin-D
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Osteil
Ostelin
Prestwick3_000420
Prestwick_554
Radiostol
Radstein
Radsterin
Rodine C
Rodinec
SMR000857106
SPECTRUM1500276
ST057150
STOCK1N-53397
Shock-ferol
Shock-ferol sterogyl
Sorex C.R
Sorex C.R.
Spectrum5_000666
Sterogyl
Synthetic Vitamin D
UNII-VS041H42XC
Uvesterol D
Uvesterol-D
VITAMIN D2
VITAMIN D2 WATER DISPERSABLE U.S.P.
VITAMIN_D2
Vigantol
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in Oil
Vitamin D2
Vitamin- D2
Vitamin-?D2
Vitamina D2
Vitavel-D
WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ
ZINC04474571
ZINC04629876
beta-Ol
bmse000510
component of Geltabs Vitamin D
delta-Arthin
delta-Tracetten
ergocalciferol
vitamin d-2
12tannic acidapproved, NutraceuticalPhase 4, Phase 31892
13Neurotransmitter AgentsPhase 4, Phase 2, Phase 3, Phase 117734
14Antiviral AgentsPhase 4, Phase 3, Phase 1, Phase 29732
15Anti-Infective AgentsPhase 4, Phase 3, Phase 1, Phase 221402
16Neurotransmitter Uptake InhibitorsPhase 4, Phase 2, Phase 33464
17Protective AgentsPhase 4, Phase 2, Phase 3, Phase 17190
18Serotonin AgentsPhase 4, Phase 3, Phase 23102
19Serotonin Uptake InhibitorsPhase 4, Phase 31570
20AntioxidantsPhase 4, Phase 2, Phase 3, Phase 12928
21
SerotoninPhase 4, Phase 2, Phase 3356650-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
22Psychotropic DrugsPhase 4, Phase 2, Phase 36279
23Adrenergic AgentsPhase 4, Phase 2, Phase 3, Phase 15140
24Antidepressive AgentsPhase 4, Phase 2, Phase 32666
25Dopamine Uptake InhibitorsPhase 4, Phase 21305
26Central Nervous System StimulantsPhase 4, Phase 22132
27Vasodilator AgentsPhase 4, Phase 13438
28Bone Density Conservation AgentsPhase 4, Phase 3, Phase 23266
29Anesthetics, IntravenousPhase 42406
30Sildenafil CitratePhase 4323171599-83-0
31Phosphodiesterase InhibitorsPhase 41254
32Adjuvants, AnesthesiaPhase 4, Phase 11588
33Phosphodiesterase 5 InhibitorsPhase 4571
34ErgocalciferolsPhase 41232
35MicronutrientsPhase 4, Phase 2, Phase 3, Phase 15802
36VitaminsPhase 4, Phase 2, Phase 3, Phase 15095
37Dopamine AgentsPhase 4, Phase 2, Phase 33759
38AnestheticsPhase 4, Phase 3, Phase 19001
39Anesthetics, GeneralPhase 42787
40Trace ElementsPhase 4, Phase 2, Phase 3, Phase 15802
41vitamin dPhase 4, Phase 21653
42Central Nervous System DepressantsPhase 4, Phase 2, Phase 3, Phase 112806
43interferonsPhase 4, Phase 32137
44HematinicsPhase 4, Phase 3, Phase 21630
45AntimetabolitesPhase 4, Phase 311774
46Epoetin alfaPhase 4, Phase 2645113427-24-0
47Liver ExtractsPhase 43868
48Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 110884
49Lisdexamfetamine DimesylatePhase 497
50Antibiotics, AntitubercularPhase 4, Phase 3, Phase 1, Phase 26972

Interventional clinical trials:

(show top 50)    (show all 228)
idNameStatusNCT IDPhase
1Sodium Oxybate in Patients With Chronic Fatigue Syndrome.Unknown statusNCT01584934Phase 4
2Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFSUnknown statusNCT00598585Phase 4
3Giardia Induced Fatigue and Functional Gastrointestinal DiseasesUnknown statusNCT00860236Phase 4
4The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal PainUnknown statusNCT01417923Phase 4
5SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE)CompletedNCT02055898Phase 4
6Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue SyndromeCompletedNCT01071044Phase 4
7The Qure Study: Q-fever Fatigue Syndrome - Response to TreatmentCompletedNCT01318356Phase 4
8Exercise Effect on Aerobic Capacity and QOL in Heart FailureCompletedNCT00013221Phase 4
9A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With FibromyalgiaCompletedNCT01173055Phase 4
10The Effects of Milnacipran on Sleep Disturbance in FibromyalgiaCompletedNCT01234675Phase 4
11Oral Melatonin Plus Zinc Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)RecruitingNCT03000777Phase 4
12Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered BreathingRecruitingNCT01368718Phase 4
13CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeSEnrolling by invitationNCT02402218Phase 4
14Use of Xyrem to Improve Sleep in Chronic Fatigue SyndromeTerminatedNCT00498485Phase 4
15Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and RibavirinTerminatedNCT00194857Phase 4
16The Effect of Milnacipran on Fatigue and Quality of Life in Lupus PatientsWithdrawnNCT01359826Phase 4
17Clinical Trial to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With CFS.Unknown statusNCT01907711Phase 2, Phase 3
18Efficacy and Safety of Fermented Velvet Antler Extract on Fatigue Recovery After ExerciseUnknown statusNCT01689467Phase 2, Phase 3
19Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple SclerosisUnknown statusNCT01149525Phase 3
20Immune-Pineal Axis Function in FibromyalgiaUnknown statusNCT02041455Phase 2, Phase 3
21Double Blind Trial of Duloxetine in Chronic Fatigue SyndromeCompletedNCT00375973Phase 2, Phase 3
22Cytokine Inhibition in Chronic Fatigue Syndrome PatientsCompletedNCT02108210Phase 2, Phase 3
23Drug Intervention in Chronic Fatigue SyndromeCompletedNCT00848692Phase 2, Phase 3
24Guanidinoacetic Acid Loading for Chronic Fatigue SyndromeCompletedNCT02213679Phase 2, Phase 3
25The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue SyndromeCompletedNCT00215800Phase 3
26Investigator Initiated Clinical Study to Explore the Efficacy and Safety of Human Placenta Hydrolysate in the Chronic Fatigue PatientsCompletedNCT01742013Phase 3
27Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS.CompletedNCT02063126Phase 2, Phase 3
28Exercise and Behavioral Therapy Trial (EBT).CompletedNCT00007748Phase 3
29Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+CompletedNCT00552682Phase 3
30Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus RibavirinCompletedNCT00196664Phase 3
31Online Acceptance-based Behavioural Treatment for FibromyalgiaCompletedNCT01642810Phase 3
32American Ginseng in Treating Patients With Fatigue Caused by CancerCompletedNCT00719563Phase 3
33St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for CancerCompletedNCT00005805Phase 3
34Study and Treatment of Post Lyme Disease (STOP-LD)CompletedNCT00000937Phase 3
35Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
36Fibromyalgia Treatment Trial With Gabapentin and Osteopathic Manipulative MedicineCompletedNCT01107574Phase 3
37Tailored Treatments of FibromyalgiaCompletedNCT00000422Phase 2, Phase 3
38Cognitive Behavioral Insomnia Therapy for Individuals With FibromyalgiaCompletedNCT00321451Phase 2, Phase 3
39Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell TransplantCompletedNCT00305851Phase 3
40Study of Milnacipran for the Treatment of FibromyalgiaCompletedNCT00098124Phase 3
41Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By SurgeryCompletedNCT00316914Phase 3
42Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With CancerCompletedNCT00661999Phase 3
43Efficacy and Safety of Abatacept in Patients With Primary Sjögren's SyndromeRecruitingNCT02067910Phase 3
44Combined Western and Traditional Chinese Medicine Daycare for CKD PatientsRecruitingNCT02545036Phase 3
45Probiotic (Visbiome) for Gulf War IllnessRecruitingNCT02011542Phase 2, Phase 3
46Evaluation of Spa Therapy in the Treatment of FibromyalgiaRecruitingNCT02265029Phase 3
47A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)RecruitingNCT01376778Phase 3
48ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)RecruitingNCT02946463Phase 3
49Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaRecruitingNCT02085408Phase 3
50Ampligen in Chronic Fatigue SyndromeActive, not recruitingNCT00215813Phase 3

Search NIH Clinical Center for Chronic Fatigue Syndrome

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: fatigue syndrome, chronic

Genetic Tests for Chronic Fatigue Syndrome

About this section

Anatomical Context for Chronic Fatigue Syndrome

About this section

MalaCards organs/tissues related to Chronic Fatigue Syndrome:

36
Testes, Brain, Heart, Lymph node, Prostate, B cells, Pituitary

Publications for Chronic Fatigue Syndrome

About this section

Articles related to Chronic Fatigue Syndrome:

(show top 50)    (show all 783)
idTitleAuthorsYear
1
Treatment and management of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: all roads lead to Rome. (28052319)
2017
2
Metabolic profiling of a myalgic encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism. (28059425)
2017
3
Poor sleep quality is associated with greater circulating pro-inflammatory cytokines and severity and frequency of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) symptoms in women. (28038892)
2017
4
Fatigue and psychosocial variables in autoimmune rheumatic disease and chronic fatigue syndrome: A cross-sectional comparison. (27998507)
2017
5
Children's experiences of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review and meta-ethnography of qualitative studies. (28087544)
2017
6
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis. (28066845)
2016
7
Mitochondrial dysfunction in a family with psychosis and chronic fatigue syndrome. (27989882)
2016
8
Metabolic features of chronic fatigue syndrome. (27573827)
2016
9
Association of biomarkers with health-related quality of life and history of stressors in myalgic encephalomyelitis/chronic fatigue syndrome patients. (27580693)
2016
10
The utility of patient-reported outcome measures among patients with myalgic encephalomyelitis/chronic fatigue syndrome. (27600520)
2016
11
Progressive brain changes in patients with chronic fatigue syndrome: A longitudinal MRI study. (27123773)
2016
12
Mortality in Patients with Myalgic Encephalomyelitis and Chronic Fatigue Syndrome. (28070451)
2016
13
Epistemic injustice in healthcare encounters: evidence from chronic fatigue syndrome. (27920164)
2016
14
Assessing the reliability of the five minute speech sample against the Camberwell family interview in a chronic fatigue syndrome sample. (27095328)
2016
15
A UK based review of recommendations regarding the management of chronic fatigue syndrome. (27521650)
2016
16
Housebound versus nonhousebound patients with myalgic encephalomyelitis and chronic fatigue syndrome. (27127189)
2016
17
Obesity in adolescents with chronic fatigue syndrome: an observational study. (27655658)
2016
18
Adiponectin potentially contributes to the anti-depressive effects of Baduanjin Qigong exercise in women with chronic fatigue syndrome-like illness. (27938498)
2016
19
The Relationship between Age and Illness Duration in Chronic Fatigue Syndrome. (27110826)
2016
20
Enhanced psychological flexibility and improved quality of life in chronic fatigue syndrome/myalgic encephalomyelitis. (27521652)
2016
21
Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome. (27536947)
2016
22
High-frequency rTMS for the Treatment of Chronic Fatigue Syndrome: A Case Series. (27904120)
2016
23
Review: Exercise therapy reduces fatigue in chronic fatigue syndrome. (27182921)
2016
24
Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. (28018972)
2016
25
Do evidence based interventions for chronic fatigue syndrome improve sleep? A systematic review and narrative synthesis. (27524207)
2016
26
Metabolic mechanism of a polysaccharide from Schisandra chinensis to relieve chronic fatigue syndrome. (27545408)
2016
27
Exploring the potential role of the advanced nurse practitioner within a care path for patients with chronic fatigue syndrome. (28000331)
2016
28
Factors determining fatigue in the chronic fatigue syndrome: a path analysis. (27143625)
2016
29
Fatigue Exacerbation by Interval or Continuous Exercise in Chronic Fatigue Syndrome. (27183124)
2016
30
Reply to: Myalgic Encephalomyelitis, chronic fatigue syndrome or systemic exercise intolerance disease: What's in a name? (27931912)
2016
31
Graded vs Intermittent Exercise Effects on Lymphocytes in Chronic Fatigue Syndrome. (27116645)
2016
32
Chronic fatigue syndrome in women assessed with combined cardiac magnetic resonance imaging. (27561279)
2016
33
Emotional conflict processing in adolescent chronic fatigue syndrome: A pilot study using functional magnetic resonance imaging. (27647312)
2016
34
CDC Grand Rounds: Chronic Fatigue Syndrome - Advancing Research and Clinical Education. (28033311)
2016
35
Dysregulation of Protein Kinase Gene Expression in NK Cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients. (27594784)
2016
36
The psychological impact of dependency in adults with chronic fatigue syndrome/myalgic encephalomyelitis: A qualitative exploration. (27098385)
2016
37
Altered neuroendocrine control and association to clinical symptoms in adolescent chronic fatigue syndrome: a cross-sectional study. (27149955)
2016
38
Activation of the NLRP3 inflammasome in lipopolysaccharide-induced mouse fatigue and its relevance to chronic fatigue syndrome. (27048470)
2016
39
Ubiquinol-10 supplementation improves autonomic nervous function and cognitive function in chronic fatigue syndrome. (27125909)
2016
40
Reversal of Refractory Ulcerative Colitis and Severe Chronic Fatigue Syndrome Symptoms Arising from Immune Disturbance in an HLA-DR/DQ Genetically Susceptible Individual with Multiple Biotoxin Exposures. (27165859)
2016
41
Autonomic correlations with MRI are abnormal in the brainstem vasomotor centre in Chronic Fatigue Syndrome. (27114901)
2016
42
Comorbidities treated in primary care in children with chronic fatigue syndrome / myalgic encephalomyelitis: A nationwide registry linkage study from Norway. (27590471)
2016
43
Emotional Suppression in Chronic Fatigue Syndrome: Experimental Study. (27183308)
2016
44
Genetic evaluation of AMPD1, CPT2, and PGYM metabolic enzymes in patients with chronic fatigue syndrome. (27525900)
2016
45
A qualitative investigation of eating difficulties in adolescents with chronic fatigue syndrome/myalgic encephalomyelitis. (27215228)
2016
46
Cow's Milk Protein Intolerance in Adolescents and Young Adults with Chronic Fatigue Syndrome. (27177188)
2016
47
Association of mitochondrial DNA variants with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) symptoms. (27998272)
2016
48
Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome. (27099524)
2016
49
Myalgic Encephalomyelitis, chronic fatigue syndrome or systemic exercise intolerance disease: What's in a name? (27969082)
2016
50
For chronic fatigue syndrome, a 'shifting tide' at NIH. (27846583)
2016

Variations for Chronic Fatigue Syndrome

About this section

Expression for genes affiliated with Chronic Fatigue Syndrome

About this section
Search GEO for disease gene expression data for Chronic Fatigue Syndrome.

Pathways for genes affiliated with Chronic Fatigue Syndrome

About this section

Pathways related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show all 50)
idSuper pathwaysScoreTop Affiliating Genes
110.1CRH, POMC
2
Show member pathways
9.8COMT, MAOA
39.7IL1B, IL6, TGFB1
49.6IL10, IL2, IL6
59.5CRH, IL2, POMC, TGFB1
6
Show member pathways
9.4IL1B, MAOA, SLC6A4, TNF
7
Show member pathways
9.3CXCL8, IL2, TNF
89.3IL10, IL6, TGFB1, TNF
99.3IL10, IL2, IL6, TNF
10
Show member pathways
9.3IL10, IL2, TGFB1, TNF
119.3IL10, IL1B, IL6, TNF
129.3IL10, IL1B, IL6, TNF
13
Show member pathways
9.2IL10, IL1B, TGFB1, TNF
149.2IL10, IL1B, IL2, TNF
15
Show member pathways
9.2IGF1, IL10, IL6, TGFB1
169.2HTR1A, HTR2A, MAOA, SLC6A4
17
Show member pathways
9.1CXCL8, IL1B, IL6, TNF
189.1CXCL8, IL1B, IL6, TNF
19
Show member pathways
9.1CXCL8, IL1B, IL6, TNF
20
Show member pathways
9.1CXCL8, IL1B, IL6, TNF
219.0CXCL8, IL2, IL6, NR3C1, POMC
229.0IGF1, IL6, NR3C1, TGFB1, TNF
239.0IL10, IL1B, IL6, TGFB1, TNF
249.0IGF1, IL1B, IL6, NR3C1, TNF
258.9CXCL8, IL2, IL6, NR3C1, TNF
268.8CXCL8, IL1B, IL6, TGFB1, TNF
278.8CXCL8, IL1B, IL6, TGFB1, TNF
288.7CXCL8, IL10, IL1B, IL6, TNF
29
Show member pathways
8.7IL10, IL1B, IL2, IL6, TGFB1, TNF
308.7IL10, IL1B, IL2, IL6, TGFB1, TNF
31
Show member pathways
8.7IL10, IL1B, IL2, IL6, TGFB1, TNF
32
Show member pathways
8.7IL10, IL1B, IL2, IL6, TGFB1, TNF
338.7IL10, IL1B, IL2, IL6, TGFB1, TNF
348.6EIF2AK2, IGF1, TGFB1, TNF
358.6CXCL8, EIF2AK2, RNASEL, TNF
368.5CXCL8, IGF1, IL1B, IL6, RNASEL, TGFB1
378.5CXCL8, IL1B, IL2, IL6, TGFB1, TNF
388.5CXCL8, IL10, IL1B, IL6, TGFB1, TNF
398.5CXCL8, IL10, IL1B, IL6, TGFB1, TNF
408.5CXCL8, IL10, IL1B, IL2, IL6, TNF
41
Show member pathways
8.3CXCL8, IL10, IL1B, IL2, IL6, RNASEL
42
Show member pathways
8.2CXCL8, IL10, IL1B, IL2, IL6, TGFB1
43
Show member pathways
8.1EIF2AK2, IL10, IL1B, IL2, IL6, TNF
44
Show member pathways
7.8EIF2AK2, IGF1, IL1B, IL2, IL6, TGFB1
45
Show member pathways
7.8CXCL8, IGF1, IL10, IL1B, IL2, IL6
46
Show member pathways
7.8CXCL8, IGF1, IL10, IL1B, IL2, IL6
47
Show member pathways
7.8CXCL8, IGF1, IL10, IL1B, IL2, IL6
48
Show member pathways
7.8CXCL8, EIF2AK2, IL1B, IL2, IL6, RNASEL
49
Show member pathways
7.3CXCL8, EIF2AK2, IGF1, IL10, IL1B, IL2
507.2CXCL8, HTR1A, HTR2A, IL10, IL1B, IL6

GO Terms for genes affiliated with Chronic Fatigue Syndrome

About this section

Cellular components related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular regionGO:00055768.4CRH, CXCL8, IGF1, IL1B, IL2, IL6
2extracellular spaceGO:00056157.4CRH, CXCL8, IGF1, IL10, IL1B, IL2

Biological processes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show top 50)    (show all 59)
idNameGO IDScoreTop Affiliating Genes
1regulation of serotonin secretionGO:001406210.7CRH, HTR1A
2positive regulation of immunoglobulin secretionGO:005102410.7IL2, IL6
3positive regulation of regulatory T cell differentiationGO:004559110.7IL2, TGFB1
4epithelial cell proliferation involved in salivary gland morphogenesisGO:006066410.7IL6, TNF
5negative regulation of lipid storageGO:001088810.7IL6, TNF
6positive regulation of mononuclear cell migrationGO:007167710.6TGFB1, TNF
7chronic inflammatory response to antigenic stimulusGO:000243910.6IL1B, TNF
8positive regulation of calcidiol 1-monooxygenase activityGO:006055910.6IL1B, TNF
9positive regulation of chemokine biosynthetic processGO:004508010.6IL1B, TNF
10positive regulation of fever generationGO:003162210.6IL1B, TNF
11positive regulation of heterotypic cell-cell adhesionGO:003411610.6IL1B, TNF
12negative regulation of cytokine secretion involved in immune responseGO:000274010.6IL10, TNF
13dopamine catabolic processGO:004242010.6COMT, MAOA
14neurotransmitter catabolic processGO:004213510.6COMT, MAOA
15cellular response to dexamethasone stimulusGO:007154910.6CRH, IL6, TGFB1
16regulation of establishment of endothelial barrierGO:190314010.5IL1B, TNF
17receptor biosynthetic processGO:003280010.5IL10, TNF
18negative regulation of fat cell differentiationGO:004559910.4IL6, TGFB1, TNF
19positive regulation of T cell proliferationGO:004210210.4IL1B, IL2, IL6
20positive regulation of peptidyl-serine phosphorylationGO:003313810.4IL6, TGFB1, TNF
21lipopolysaccharide-mediated signaling pathwayGO:003166310.4IL1B, TGFB1, TNF
22positive regulation of interleukin-6 productionGO:003275510.3IL1B, IL6, TNF
23positive regulation of nitric oxide biosynthetic processGO:004542910.3IL1B, IL6, TNF
24positive regulation of epithelial cell proliferationGO:005067910.3IGF1, IL6, TGFB1
25positive regulation of interferon-gamma productionGO:003272910.3IL1B, IL2, TNF
26regulation of behaviorGO:005079510.3HTR1A, HTR2A
27regulation of hormone secretionGO:004688310.3HTR1A, HTR2A
28cellular response to estradiol stimulusGO:007139210.3IGF1, IL10, IL6
29positive regulation of smooth muscle cell proliferationGO:004866110.2IGF1, IL6, TNF
30response to heatGO:000940810.2IGF1, IL1B, IL6
31response to molecule of bacterial originGO:000223710.2CXCL8, IL10
32sequestering of triglycerideGO:003073010.0IL1B, TNF
33serotonin metabolic processGO:004242810.0HTR1A, MAOA
34positive regulation of sequence-specific DNA binding transcription factor activityGO:005109110.0IL10, IL1B, IL6, TNF
35positive regulation of MAP kinase activityGO:004340610.0HTR2A, TGFB1, TNF
36female pregnancyGO:00075659.9COMT, CRH, IGF1, TGFB1
37negative regulation of viral genome replicationGO:00450719.9EIF2AK2, RNASEL, TNF
38response to hypoxiaGO:00016669.9IGF1, IL1B, SLC6A4, TGFB1
39protein kinase B signalingGO:00434919.8IGF1, IL1B, TGFB1, TNF
40positive regulation of protein phosphorylationGO:00019349.8CRH, IL1B, IL2, TGFB1, TNF
41positive regulation of chemokine productionGO:00327229.8EIF2AK2, IL6, TNF
42cellular response to lipopolysaccharideGO:00712229.8CXCL8, IL10, IL6, TNF
43regulation of hematopoietic progenitor cell differentiationGO:19015329.8EIF2AK2, PDCD2
44response to glucocorticoidGO:00513849.8IGF1, IL10, IL6, TNF
45positive regulation of ERK1 and ERK2 cascadeGO:00703749.7HTR2A, IL1B, IL6, TNF
46memoryGO:00076139.7HTR2A, IGF1, IL1B, SLC6A4
47positive regulation of peptidyl-tyrosine phosphorylationGO:00507319.7HTR2A, IGF1, IL6, TGFB1
48positive regulation of gene expressionGO:00106289.6CRH, IL1B, IL6, SLC6A4, TGFB1, TNF
49response to organic substanceGO:00100339.6IL10, SLC6A4, TGFB1, TNF
50positive regulation of transcription, DNA-templatedGO:00458939.3IGF1, IL10, IL1B, IL6, TGFB1, TNF

Molecular functions related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1serotonin bindingGO:00513789.6HTR2A, MAOA
2cytokine activityGO:00051259.3IL10, IL1B, IL2, IL6, TGFB1, TNF
3growth factor activityGO:00080839.2IGF1, IL10, IL2, IL6, TGFB1

Sources for Chronic Fatigue Syndrome

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet